Literature DB >> 33401251

LncRNA ROR1-AS1 accelerates osteosarcoma invasion and proliferation through modulating miR-504.

Xiangkun Wu1, Lihua Yan2, Yongxi Liu1, Lilin Shang1.   

Abstract

Long non-coding RNAs (LncRNAs) play vital roles in the progression and development of tumors. However, the functional role of ROR1-AS1 in osteosarcoma has not been investigated. We found that ROR1-AS1 was upregulated in osteosarcoma tissues compared to non-tumor samples. Elevated expression of ROR1-AS1 promoted cyclin D1, PCNA and ki-67 expression and increased cell cycle and growth in MG-63 cell. Moreover, overexpression of ROR1-AS1 induced cell migration in MG-63 cell, promoting N-cadherin and vimentin expression and inhibiting E-cadherin expression. Dual-luciferase assay proved that ROR1-AS1 served as one sponge for miR-504 and ROR1-AS1 overexpression suppressed miR-504 expression in MG-63 cell. ROR1-AS1 expression was lower in osteosarcoma tissues compared to non-tumor samples. Pearson's correlation assay showed a negative correlation between miR-504 and ROR1-AS1 expression. MiR-504 overexpression partly abrogated ROR1-AS1-induced effects on osteosarcoma cell migration and proliferation. These data implied that ROR1-AS1 played as an oncogene and might be a new treatment target for osteosarcoma.

Entities:  

Keywords:  ROR1-AS1; miR-504; osteosarcoma

Mesh:

Substances:

Year:  2020        PMID: 33401251      PMCID: PMC7835057          DOI: 10.18632/aging.103498

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  42 in total

1.  miR-193b availability is antagonized by LncRNA-SNHG7 for FAIM2-induced tumour progression in non-small cell lung cancer.

Authors:  Kelin She; Hui Yan; Jun Huang; Huaping Zhou; Jianxing He
Journal:  Cell Prolif       Date:  2017-11-12       Impact factor: 6.831

2.  MicroRNA-32 inhibits osteosarcoma cell proliferation and invasion by targeting Sox9.

Authors:  Jian-Qiang Xu; Wei-Bin Zhang; Rong Wan; Yao-Qi Yang
Journal:  Tumour Biol       Date:  2014-07-03

3.  Long non-coding RNA ROR1-AS1 enhances colorectal cancer metastasis by targeting miR-375.

Authors:  F-Z Wang; M-Q Zhang; L Zhang; M-C Zhang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2019-08       Impact factor: 3.507

Review 4.  Long non-coding PANDAR as a novel biomarker in human cancer: A systematic review.

Authors:  Yifan Zou; Yuantang Zhong; Junjie Wu; Huizhong Xiao; Xintao Zhang; Xinhui Liao; Jianfa Li; Xuhua Mao; Yuchen Liu; Fuyou Zhang
Journal:  Cell Prolif       Date:  2017-12-10       Impact factor: 6.831

5.  microRNA-377 suppresses the proliferation of human osteosarcoma MG-63 cells by targeting CDK6.

Authors:  Liang Wang; Jianli Shao; Xia Zhang; Meng Xu; Jianfu Zhao
Journal:  Tumour Biol       Date:  2015-01-11

6.  ROR1-AS1 promotes tumorigenesis of colorectal cancer via targeting Wnt/β-catenin.

Authors:  T Liao; S-L-M Maierdan; C Lv
Journal:  Eur Rev Med Pharmacol Sci       Date:  2019-08       Impact factor: 3.507

7.  Long non-coding RNA CDKN2B-AS1 promotes osteosarcoma by increasing the expression of MAP3K3 via sponging miR-4458.

Authors:  Daokun Gui; Hanqi Cao
Journal:  In Vitro Cell Dev Biol Anim       Date:  2020-01-16       Impact factor: 2.416

8.  Long noncoding RNA ZEB1-AS1 promotes the tumorigenesis of glioma cancer cells by modulating the miR-200c/141-ZEB1 axis.

Authors:  Lei Meng; Pengju Ma; Ruiyan Cai; Qingkai Guan; Mingying Wang; Baozhe Jin
Journal:  Am J Transl Res       Date:  2018-11-15       Impact factor: 4.060

9.  MicroRNA-153 inhibits osteosarcoma cells proliferation and invasion by targeting TGF-β2.

Authors:  Guangfeng Niu; Bin Li; Li Sun; Chenggong An
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

10.  Long non-coding RNA ROR1-AS1 induces tumorigenesis of colorectal cancer by affecting Wnt/β-catenin signaling pathway.

Authors:  Wei Wang; Weihong Zheng; Lei Zhang; Ke Li
Journal:  Biosci Rep       Date:  2019-11-29       Impact factor: 3.840

View more
  1 in total

Review 1.  The roles of glycolysis in osteosarcoma.

Authors:  Zuxi Feng; Yanghuan Ou; Liang Hao
Journal:  Front Pharmacol       Date:  2022-08-17       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.